Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...

JIA, formerly known as “Juvenile Rheumatoid Arthritis,” is an autoimmune disease of unknown cause. The arthritic condition affects an estimated 300,000 children in the United States and ...

Several known risk factors of Dermatomyositis (DM) include female sex, genetics, ultraviolet radiation, prior respiratory disease, viral and bacterial infections, medications, and pollutants and ...

From 2014 to 2018, Gleason served as vice president for research at the Cure JM Foundation, which advocates for research, education and funding for juvenile dermatomyositis treatments. It was ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Juvenile dermatomyositis (JDM) is a rare autoimmune condition with insufficient biomarkers and treatments, in part, due to incomplete knowledge of the cell types mediating disease. We investigated ...

MONONGALIA COUNTY, W.Va (WDTV) - UPDATE (3/14 at 3 p.m.): A juvenile, reported missing out of Monongalia County earlier this week, has been found safe. According to the Monongalia County Sheriff ...

In subtypes such as dermatomyositis, immune-mediated necrotizing myopathy ... mesenchymal stem cell-derived exosomes (MSC-Exos), JAK inhibitors, anifrolumab, and dazukibart. TO belonged to the Social ...